Journal
ONCOLOGY
Volume 77, Issue 5, Pages 300-303Publisher
KARGER
DOI: 10.1159/000259616
Keywords
Pancreatic cancer; Chemotherapy; Gemcitabine; S-1
Categories
Ask authors/readers for more resources
Objectives: We performed a pilot study of a modified combination chemotherapy regimen with S-1 plus gemcitabine for patients with advanced pancreatic cancer. Methods: Gemcitabine was administered at a dose of 1,000 mg/m(2) in a 30-min intravenous injection on days 1 and 15. S-1 was administered orally at a dose of 40 mg/m(2) twice daily for 14 consecutive days followed by a 14-day rest. Each cycle was repeated every 28 days. Results: Sixteen patients were enrolled. No complete response was observed and partial response was observed in 5 patients (31.3%), stable disease in 10 patients (62.5%) and progressive disease in 1 patient (6.3%). The median time to progression was 10.0 months (95% CI 4.4-N.A.) and the median survival time was 20.4 months (95% CI 8.6-24.1 months). The major toxicities were grade 3 neutropenia (25.0%) and grade 3 anemia (6.3%). There were no grade 4 toxicities. Conclusions: Combination therapy with gemcitabine and S-1 using the modified 4-week schedule was well tolerated and efficacious for advanced pancreatic cancer. Copyright (C) 2009 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available